[ TRANSACTION RECORD ]
Novo Holdings A/S Investment in MorphoSys — 2024
VERIFIED VECTOR
ID: 001912 · tx-108-2
M SOURCE NODE — FUNDER
$2,900,000,000
EQUITY
31/05/2024
Q DESTINATION NODE — RECIPIENT
Funder Profile
[ M ]
Recipient Profile
[ Q ]
Intelligence Note
Novartis completed a 2.9 billion dollar tender offer for MorphoSys to strengthen its oncology pipeline with advanced treatments for blood cancers. The transaction includes pelabresib, a promising therapy for myelofibrosis. This deal reflects the continued focus of major pharmaceutical firms on acquiring established biotech companies with proven therapeutic platforms.